India gave emergency use authorization for a Covid-19 antibody drug cocktail developed by Roche and Regeneron, expanding the company’s arsenal of drugs to battle a massive second wave of infections. The decision was taken based on data filed with the U.S. regulators and the scientific opinion of a European regulatory panel, Roche’s India distribution partner for the drug, Cipla, said on May 5.

New cases of Covid-19 in the United States fell for a third week in a row, dropping 15 percent during the week ended May 2 to 347,000 – the lowest weekly total since October – according to a Reuters analysis of state and county data.

India postponed exams for trainee doctors and nurses on May 3, freeing them up to fight the world’s biggest surge in coronavirus infections, as the health system crumbles under the weight of new cases and hospitals run out of beds and oxygen.

Several states in India ran out of vaccines against Covid-19, exacerbating a dire second wave of infections that has left hospitals and morgues overflowing while families scramble for increasingly scarce medicines and oxygen.

India’s total Covid-19 cases passed 18 million on April 29 after another world record number of daily infections, as gravediggers worked around the clock to bury victims and hundreds more were cremated in makeshift pyres in parks and parking lots.

Pfizer is expanding the company’s presence in infectious diseases with the acquisition of San Diego-based Amplyx Pharmaceuticals and the lead antifungal compound Fosmanogepix (APX001).

Novartis said on Tuesday that a large British study of the Swiss drugmaker’s cholesterol-lowering medicine Leqvio is not expected to be completed until 2026, a year later than expected, as Covid-19 infections made participant recruitment difficult.

With Lyme disease season emerging and the Covid-19 pandemic still with us, an important webinar designed to help physicians differentiate between the two (as well as the flu) so as to provide timely diagnosis and treatment for their patients will be held on Wednesday, May 5. The webinar is the latest in an ongoing series sponsored by Quidel, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions.

New cases of Covid-19 in the United States fell 16 percent in the week ended April 25 to about 409,000, the largest percentage drop in weekly new cases since February, according to a Reuters analysis of state and county data.

As a massive Covid-19 surge continues to rage on throughout India, scientists and public health officials scramble to determine whether currently authorized vaccines in the country can provide a mitigation effect to this unprecedented spread. A new study published online has provided some hope, with researchers suggesting that the Covaxin vaccine – developed by Bharat Biotech and Pennsylvania-based Ocugen – could neutralize the SARS-CoV-2 variant leading the second wave in India.